EMPLOYMENT AGREEMENT
Exhibit. 10.12
EMPLOYMENT AGREEMENT
EMPLOYMENT AGREEMENT, dated as of September 2, 2016 (the “Effective Date”), between D3 MEDICINE LLC (the “Company”), and Xxxxxxx Xxxxx (the “Executive”).
WHEREAS, the Company has entered into the Membership Interest Purchase Agreement, dated as of September 2, 2016 (the “Purchase Agreement”) among Certara USA, Inc., the Company and the Sellers listed on Exhibit A to the Purchase Agreement; and
WHEREAS, contingent on the Closing (as defined in the Purchase Agreement), the Company and Executive desire to embody the terms and conditions of Executive’s employment with the Company in a written employment agreement, which will supersede all prior agreements, whether written or oral, between the Company and Executive.
NOW, THEREFORE, in consideration of the mutual promises and covenants set forth in this Agreement, the Parties agree as follows:
1. | Employment Duties and Acceptance. |
Exhibit. 10.12
3. | Compensation. |
$250,000.00 per annum, payable not less frequently than monthly, less such deductions as shall be required to be withheld by applicable rules and regulations (the “Base Salary”). The Base Salary shall not preclude raises, incentive bonus plans and other compensation or incentives, including equity incentives should the Board, in its sole and absolute discretion, so determine to provide such additional compensation or incentives to the Executive. Executive’s compensation shall be reviewed at least once per year.
Exhibit. 10.12
4. | Termination. |
5.5 and the Executive has entered into an effective general release of claims reasonably satisfactory to the Company that becomes effective and irrevocable by no later than the 30th day after Executive’s termination of employment, the Executive shall have the right to:
For purposes of this Agreement:
Exhibit. 10.12
“Accrued Obligations” means as of the date of Executive’s termination, (a) Executive’s earned but unpaid Base Salary, if any, through such date, (b) any unreimbursed business expenses payable to Executive pursuant to applicable Company policy and (c) any Incentive Bonus awarded by the Board but not previously paid to the Executive with respect to the fiscal year preceding the fiscal year in which such date of termination occurs.
“Cause” means (i) Executive’s conviction of, or plea of nolo contendere to, a felony or to any other crime involving fraud, dishonesty or breach of trust, (ii) Executive’s gross negligence or intentional misconduct in the performance of Executive’s duties to the Company, Executive’s failure to perform at a standard reasonably expected of an employee in Executive’s position with the Company, or Executive’s failure to devote Executive’s full business time to the Company, after the Company has delivered to Executive a written demand for performance which describes the basis for the Company’s belief that Executive has not substantially performed Executive’s duties and provides Executive with thirty (30) days to cure such failure,
(iii) Executive’s fraud or willful dishonesty or misrepresentation intended to result in direct or indirect gain or personal enrichment at the expense of the Company or its equity holders, (iv) Executive’s public or consistent drunkenness or illegal use of narcotics that is reasonably likely to become materially injurious to the reputation or business of the Company or that is reasonably likely to impair Executive’s performance of duties to the Company, (v) the failure of the Executive to follow the reasonable directions of the Board or the individual(s) to whom such Executive reports, after the Company has delivered to Executive a written demand for performance which describes the basis for the Company’s belief that Executive has not followed such directions and provides Executive with thirty (30) days to cure such failure; or (vi) any other intentional conduct of Executive that materially injures the Company or its reputation.
“Good Reason” means (a) a material diminution in Executive’s authority, duties, or responsibilities, (b) the principal place of employment of the Executive is relocated to any location which is outside of a 50 mile radius of the Employment Location, or (c) a material reduction in Executive’s Base Salary (other than a general reduction in Base Salary that affects all similarly situated executives in substantially the same proportions); provided that Good Reason shall not exist unless (i) within twenty (20) days after the occurrence of such act the Executive gives written notice to the Company stating that such act constitutes Good Reason, is not acceptable to the Executive, and requesting that the Company cure such act and (ii) the Executive terminates his or her employment with the Company within ninety (90) days after delivery of such notice.
Exhibit. 10.12
5. | Confidentiality, Intellectual Property, Noncompete and Nonsolicitation. |
(b) lawfully obtainable from other sources or which is in the public domain through no fault of the Executive; or (c) the disclosure of which is consented to in writing by the Company.
Exhibit. 10.12
containing any Confidential Information or Intellectual Property) irrespective of the location or form of such material and, if requested by the Company, will provide the Company with written confirmation that all such materials have been delivered to the Company.
Executive’s services are of special, unique and extraordinary value to the Company. Therefore, the Executive hereby agrees that at any time during his or her employment with the Company and for a period of twelve (12) months thereafter (the “Noncompetition Period”), the Executive will not directly or indirectly own, manage, control, participate in, consult with, render services for or in any manner engage in any business, including pharmaceutical or research organizations, worldwide competing with the businesses of the Company or the Company Group, as such businesses exist or are in the process or being planned as of the termination of Executive’s employment. It shall not be considered a violation of this Section 5.4 for the Executive to be a passive owner of not more than 2% of the outstanding stock of any class of a competing corporation which is publicly traded, so long as the Executive has no active participation in the business of such corporation.
Exhibit. 10.12
covenants remain in force. The Executive further covenants that the Executive will not challenge the reasonableness or enforceability of any of the covenants set forth in this Section 5, and that the Executive will reimburse the Company and/or the Company Group (including reasonable attorneys’ fees) incurred in connection with any action to enforce any of the provision of this Section 5 if any of the Company Group prevails on any material issue involved in such dispute or if the Executive challenges the reasonableness or enforceability of any of the provisions of this Section 5. The Executive acknowledges that any violation of this Section 5 will result in irreparable injury to the Company Group and agrees that the Company shall be entitled to seek preliminary and permanent injunctive relief, without the necessity of proving actual damages, as well as an equitable accounting of all earnings, profits and other benefits arising from any violation of this Section 5 by the Executive, which rights shall be cumulative and in addition to any other rights or remedies to which the Company may be entitled. Without limiting the generality of the foregoing, the Noncompetition Period and Nonsolicitation Period shall be extended for an additional period equal to any period during which the Executive is in breach of the Executive’s obligations under this Section 5. The Executive represents and acknowledges that (i) the Executive has been advised by the Company to consult the Executive’s own legal counsel in respect of this Agreement, and (ii) the Executive has had full opportunity, prior to execution of this Agreement, to review thoroughly this Agreement with the Executive’s counsel.
6. | Other Provisions. |
if to the Company, at: D3 MEDICINE LLC
0 Xxxxxxx Xxxxx, 0xx Xxxxx
Parsippany, NJ 07054 Attn: SVP, HR
With a copy to:
Attn: Xxxx Xxxxxxxxx C/O Certara
100 Overlook Center #101
Princeton, NJ 08540 if to the Executive, at: Xxxxxxx Xxxxx
Exhibit. 10.12
4 Navajo Ct.
Montville, NJ 07045
Exhibit. 10.12
the assets of the Company and such assignee or transferee assumes by operation of law or in a writing duly executed by the assignee or transferee all of the liabilities, obligations and duties of the Company, as contained in this Agreement, either contractually or as a matter of law, as if no such assignment or transfer had taken place.
6.11 | Section 409A. |
Exhibit. 10.12
signature page follows
Exhibit 10.12
IN WITNESS WHEREOF, the parties have executed this Agreement the date first above written.
D3 MEDICINE LLC
/s/ Xxxxxxx Xxxxx
Name: Xxxxxxx Xxxxx Title: Chief Executive Officer
Executive:
/s/ Xxxxxxx Xxxxx
Xxxxxxx Xxxxx
1 Sept 2016